A novel approach for early diagnosis and personalized therapy to pancreatic cancer by metabolic profiling

点击翻译按钮获取中文摘要

We performed metabolic profiling analysis with two Gemcitabine resistant pancreatic cancer cell lines and their parent strains by Liquid Chromatography - tandem Mass Spectrometry , then detected variance in 30 % metabolic profiling between them. Furthermore, we also performed matrix-assisted laser desorption/ionization imaging mass spectrometry with 12 resected specimens which arrayed in frozen tissue microarray. More than 40 kinds of metabolites were identified and mapped on the each section, and interestingly some of metabolites showed different distributions between normal and tumor tissue. We will investigate these identified metabolites continuously for possibility of early diagnosis and personalized medicine.